Company profile
DIANTHUS THERAPEUTICS, INC. /DE/
NASDAQ:DNTHBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CLASEPRUBART | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06537999 | phase2 | active_not_recruiting | 2024-09-17 | 2026-12-01 | Dianthus Therapeutics | A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy |
| NCT06282159 | phase2 | active_not_recruiting | 2024-02-23 | 2025-07-28 | Dianthus Therapeutics | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) |
| NCT07647510 | phase3 | recruiting | 2026-06-29 | 2028-12-01 | Dianthus Therapeutics | A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) |
| NCT06858579 | phase3 | recruiting | 2025-02-10 | 2028-12-31 | Dianthus Therapeutics | A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) |
FDA applications (0)
No records yet.